Program
pomalidomide
Also written as “Pomalidomide”, “Pomalidomide 4 MG Oral Capsule” and “Xetrane® (Pomalidomide) 4 mg Hard Capsule”.
Its studies are mostly in Multiple Myeloma · Primary Myelofibrosis · Brain Neoplasms · Scleroderma, Systemic · Hematologic Neoplasms, led by 8 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bristol-Myers Squibb | 251 open or running | phase 3since Jul 15, 2010 | Nov 7, 2003 | Jan 10, 2027phase 3 · NCT05519085 |
| Oncotherapeutics | 40 open or running | phase 2since Feb 20, 2012 | Feb 20, 2012 | none ahead |
| Amgen | 20 open or running | phase 2since Nov 22, 2019 | Oct 18, 2016 | none ahead |
| Simcere Pharmaceutical Group | 20 open or running | phase 3since Sep 24, 2016 | Sep 24, 2016 | none ahead |
| criterium-inc | 10 open or running | phase 2since Oct 19, 2011 | Oct 19, 2011 | none ahead |
| Knight Therapeutics (USA) | 10 open or running | phase 1since Jul 3, 2026 | Jul 3, 2026 | none ahead |
| megalabs | 11 open or running | phase 1since Sep 15, 2023 | Sep 15, 2023 | none ahead |
| Takeda | 10 open or running | phase 4since Dec 20, 2021 | Dec 20, 2021 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 21 studies since Nov 7, 2003.
- Dec 10, 20132 phase 2 studies in Multiple MyelomaBristol-Myers Squibb · NCT02011113, NCT02045017
- Jun 18, 2014Phase 1 study in Healthy VolunteersBristol-Myers Squibb · NCT02168205 · 55 enrolled · United States
- Jul 7, 20142 phase 2 studies in Multiple MyelomaOncotherapeutics · NCT02188368, NCT02206425
- Sep 24, 2016Simcere Pharmaceutical Group's first study: phase 3 study in Multiple MyelomaNew to Simcere Pharmaceutical GroupSimcere Pharmaceutical Group · NCT02916420 · 73 enrolled · China
- Oct 18, 2016Amgen's first study: phase 1 study in RecurrenceNew to AmgenAmgen · NCT02939183 · 61 enrolled · United States, Australia, Canada and more
- Feb 27, 2017Phase 2 study in Multiple MyelomaOncotherapeutics · NCT03104270 · 13 enrolled · United States
- Aug 18, 2017Phase 2 study in Central Nervous System NeoplasmsBristol-Myers Squibb · NCT03257631 · 53 enrolled · United States, France, Italy and more
- Dec 14, 2017Phase 1 study in Multiple MyelomaSimcere Pharmaceutical Group · NCT03424928 · 12 enrolled · China
- Aug 16, 2018Phase 3 study in Multiple MyelomaBristol-Myers Squibb · NCT03651128 · 386 enrolled · United States, Belgium, Canada and more
- Nov 22, 2019Phase 2 study in RecurrenceAmgen · NCT04191616 · 54 enrolled · United States, Denmark, Estonia and more
- Dec 20, 2021Takeda's first study: phase 4 study in Multiple MyelomaNew to TakedaTakeda · NCT05183139
- Aug 25, 2022Phase 3 study in RecurrenceBristol-Myers Squibb · NCT05519085 · 810 planned · United States, Argentina, Australia and more
- Sep 15, 2023megalabs's first study: phase 1 study in Bioequivalence StudyNew to megalabsmegalabs · NCT06058689 · 10 planned · India
- Jul 3, 2026Knight Therapeutics (USA)'s first study: phase 1 study in Pomalidomide Bioequivalence Study in Healthy VolunteersNew to Knight Therapeutics (USA)Knight Therapeutics (USA) · NCT07694011 · 34 enrolled · Chile
Ahead
- Jan 10, 2027Primary completion: phase 3 study in RecurrenceBristol-Myers Squibb · NCT05519085
TargetBeta
“CRL4(CRBN) E3 ubiquitin ligase inhibitor”ChEMBL 37, by rule
Other programs on the same 4 targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Lenalidomiderule | Bristol-Myers Squibb | phase 4 | 109 |
Studies
All 37 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07694011Pomalidomide Bioequivalence Study in Healthy Volunteers · Chile | 1 | Completed | Knight Therapeutics (USA) | Feb 5, 2025 | 34 |
| NCT06058689Bioequivalence Study · India | 1 | Not yet recruiting | megalabs | Nov 15, 2024 | 10 |
| NCT05519085Recurrence · United States, Argentina, Australia and more | 3 | Recruiting | Bristol-Myers Squibb | Jan 10, 2027 | 810 |
| NCT05183139Multiple Myeloma | 4 | Withdrawn | Takeda | Dec 31, 2026 | 0 |
| NCT04191616Recurrence · United States, Denmark, Estonia and more | 2 | Completed | Amgen | Nov 30, 2022 | 54 |
| NCT03651128Multiple Myeloma · United States, Belgium, Canada and more | 3 | Completed | Bristol-Myers Squibb | Apr 13, 2026 | 386 |
| NCT03424928Multiple Myeloma · China | 1 | Completed | Simcere Pharmaceutical Group | Jan 29, 2018 | 12 |
| NCT03257631Central Nervous System Neoplasms · United States, France, Italy and more | 2 | Completed | Bristol-Myers Squibb | Sep 14, 2023 | 53 |
| NCT03104270Multiple Myeloma · United States | 2 | Terminated | Oncotherapeutics | Oct 25, 2019 | 13 |
| NCT02939183Recurrence · United States, Australia, Canada and more | 1 | Completed | Amgen | Oct 6, 2022 | 61 |
| NCT02916420Multiple Myeloma · China | 3 | UNKNOWN | Simcere Pharmaceutical Group | Jun 2018 | 73 |
| NCT02206425Multiple Myeloma · United States | 2 | Completed | Oncotherapeutics | Jan 19, 2018 | 45 |
| NCT02188368Multiple Myeloma · United States | 2 | Terminated | Oncotherapeutics | Oct 23, 2020 | 45 |
| NCT02168205Healthy Volunteers · United States | 1 | Completed | Bristol-Myers Squibb | Sep 19, 2014 | 55 |
| NCT02045017Multiple Myeloma · Austria, France, Germany and more | 2 | Completed | Bristol-Myers Squibb | Jan 27, 2017 | 81 |
| NCT02011113Multiple Myeloma · Japan | 2 | Completed | Bristol-Myers Squibb | Sep 2014 | 36 |
| NCT01986894Clinical Pharmacology, Healthy Volunteer Study · United States | 1 | Completed | Bristol-Myers Squibb | Dec 2, 2013 | 72 |
| NCT01946477Multiple Myeloma · United States, Canada, Japan and more | 2 | Completed | Bristol-Myers Squibb | Apr 30, 2025 | 186 |
| NCT01835561Liver Diseases · United States | 1 | Completed | Bristol-Myers Squibb | Aug 16, 2014 | 32 |
| NCT01734928Multiple Myeloma · United States, Austria, Canada and more | 3 | Completed | Bristol-Myers Squibb | May 9, 2022 | 559 |
| NCT01712789Multiple Myeloma · Austria, Belgium, Denmark and more | 3 | Completed | Bristol-Myers Squibb | Dec 11, 2019 | 682 |
| NCT01707407Pharmacology, Clinical · United States | 1 | Completed | Bristol-Myers Squibb | Nov 1, 2012 | 32 |
| NCT01568294Multiple Myeloma · Japan | 1 | Completed | Bristol-Myers Squibb | Jul 8, 2015 | 12 |
| NCT01559129Scleroderma, Systemic · United States, Australia, France and more | 2 | Terminated | Bristol-Myers Squibb | Nov 3, 2016 | 23 |
| NCT01541332Multiple Myeloma · United States | 2 | UNKNOWN | Oncotherapeutics | Dec 2016 | 70 |
| NCT01522547Anemia, Sickle Cell · United States | 1 | Completed | Bristol-Myers Squibb | Oct 1, 2012 | 12 |
| NCT01497093Multiple Myeloma · United States | 1 | Completed | Bristol-Myers Squibb | Jul 23, 2019 | 34 |
| NCT01474330Healthy · United States | 1 | Completed | Bristol-Myers Squibb | Oct 1, 2011 | 33 |
| NCT01464034Multiple Myeloma · United States | 2 | Terminated | criterium-inc | Jul 2020 | 136 |
| NCT01324947Multiple Myeloma · Australia, Belgium, Canada and more | 3 | Completed | Bristol-Myers Squibb | Jul 31, 2014 | 74 |
| NCT01311687Multiple Myeloma · United States, Australia, Belgium and more | 3 | Completed | Bristol-Myers Squibb | Mar 1, 2013 | 455 |
| NCT01178281Primary Myelofibrosis · United States, Australia, Austria and more | 3 | Completed | Bristol-Myers Squibb | Jan 1, 2013 | 267 |
| NCT00833833Multiple Myeloma · United States, Canada | 2 | Completed | Bristol-Myers Squibb | Apr 2011 | 259 |
| NCT00717522Sarcoma · United States | 2 | Terminated | Bristol-Myers Squibb | Jan 1, 2009 | 7 |
| NCT00537511Carcinoma, Small Cell · United States, Canada | 2 | Terminated | Bristol-Myers Squibb | Nov 1, 2010 | 22 |
| NCT00463385Primary Myelofibrosis · United States, Austria, Italy and more | 2 | Completed | Bristol-Myers Squibb | May 1, 2009 | 88 |
| NCT00072722Prostatic Neoplasms · United States | 2 | Completed | Bristol-Myers Squibb | 36 |
How it is read
Names in the registry
- “Pomalidomide”, 41 entries
- “pomalidomide”, 4 entries
- “Pomalidomide 4 MG Oral Capsule”, 2 entries
- “Xetrane® (Pomalidomide) 4 mg Hard Capsule”, 1 entry
- “Imnovid® (Pomalidomide) 4 mg Hard Capsule”, 1 entry
Codes read as this program: CC4047.
Conditions, from the studies’ own filings
- Multiple Myeloma, 35 studies
- Primary Myelofibrosis, 2 studies
- Brain Neoplasms, 1 study
- Scleroderma, Systemic, 1 study
- Hematologic Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.